| 1 | Characterization of conformational and oligomeric states of proteins | 743 |
| 2 | Inhibitors of leishmania mexicana phosphoglycerate mutase identified by virtual screening and verified by inhibition studies | 596 |
| 3 | Identifying analogues of 2-deoxyglucose, alpha-d-glucose and beta-d-glucose-6-phosphate as potential inhibitors of human hexokinase ii for the development of anti-dengue therapeutics | 593 |
| 4 | Virtual screening for potential inhibitors of human hexokinase II for the development of anti-dengue therapeutics | 573 |
| 5 | Contemporary strategies and current trends in designing antiviral drugs against dengue fever via targeting host-based approaches | 570 |
| 6 | Interrogating novel compounds for improved anti-dengue therapies via inhibition of human hexokinase II (HKII) | 549 |
| 7 | Potential novel inhibitors of trypanosomatid phosphoglycerate mutases through ligand-based and structure-based in silico approaches | 536 |
| 8 | Identifying potential inhibitors of human hexokinase II for the development of anti-dengue therapeutics via virtual screening approaches | 524 |
| 9 | Trypanosomatid phosphoglycerate mutases have multiple
conformational and oligomeric states | 523 |
| 10 | Super binary vector system enhanced transformation frequency and expression level of polyhydroxyvalerate gene in oil palm immature embryo | 521 |
| 11 | Elucidating the analogues of 3-bromopyruvate (3-BP) as inhibitors against human hexokinase II for the development of anti-dengue drugs | 509 |
| 12 | Screening potential inhibitors of lactate dehydrogenase
from Plasmodium knowlesi via virtual screening
approaches | 508 |
| 13 | Effects of Daidzin and analogue of Ganoderma sinense on bacterially-expressed human hexokinase isoform 2 for anti-dengue drug design | 507 |
| 14 | Expression and purification of soluble bacterially-expressed human hexokinase II in E.coli system | 506 |
| 15 | Phosphoglycerate mutase from Trypanosoma brucei is hyperactivated by cobalt in vitro, but not in vivo | 490 |
| 16 | Novel compounds as potential anti-dengue therapies verified via inhibition of human hexokinase isoform II | 476 |
| 17 | Plasmodial enzymes in metabolic pathways as therapeutic targets and contemporary strategies to discover new antimalarial drugs: a review | 471 |
| 18 | Enhanced expression and purification strategy for recombinant bacterially-expressed human hexokinase II | 451 |
| 19 | Multiple oligomeric and conformational states of trypanosomatid phosphoglycerate mutases | 444 |
| 20 | Analogues of 2-Deoxyglucose as inhibitor candidates for hexokinase II identified via virtual screening analyses | 435 |
| 21 | Purifying and characterizing bacterially expressed soluble Lactate Dehydrogenase from Plasmodium knowlesi for the development of anti-malarial drugs | 403 |
| 22 | Virtual screening and in silico Interactions studies for potential antivirals and diagnostics against the spike protein from the Novel Coronavirus SARS-Cov-2 | 376 |
| 23 | Cloning and expression of lactate dehydrogenase from plasmodium knowlesi for anti-malarial drug development | 374 |
| 24 | Stimulating scientific minds among early secondary students in Malaysia: a pilot study using ‘engineering and electronics made fun’ approach | 333 |
| 25 | Potential inhibitors of Human Hexokinase II for the development of anti-dengue therapeutics identified via in silico approach | 303 |
| 26 | Analogues of Oxamate, Pyruvate, and Lactate as potential
inhibitors of Plasmodium Knowlesi lactate Dehydrogenase
identified using virtual screening and verified via
Inhibition Assays | 290 |
| 27 | Computational approaches for evaluation of malaria drug resistance in plasmodium species | 287 |
| 28 | Potential inhibitors of the glycolytic enzymes from Plasmodium knowlesi identified by virtual screening analysis | 286 |
| 29 | Cloning and characterisation of Lactate Dehydrogenase Gene from Plasmodium knowlesi in bacterial system | 284 |
| 30 | The glycolytic pathway is a target for drug discovery against tropical diseases | 257 |
